Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Generic Drugs: The Pay-for-Delay Problem

Generic Drugs: The Pay-for-Delay Problem

9781611220711
535.44 zł
481.89 zł Save 53.55 zł Tax included
Lowest price within 30 days before promotion: 481.89 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Brand-name pharmaceutical companies can delay generic competition that lowers prices by agreeing to pay a generic competitor to hold its competing product off the market for a certain period of time. These so-called pay-for-delay agreements have arisen as part of patent litigation settlement agreements between brand-name and generic pharmaceutical companies. Pay-for-delay agreements are win-win for the companies:: brand name pharmaceutical prices stay high, and the brand and generic share the benefits of the brands monopoly profits. Consumers lose, however:: they miss out on generic prices that can be as much as 90 percent less than brand prices. For example, brand-name medication that costs $300 per month, might be sold as a generic for as little as $30 per month. This book examines the pay-for-delay program and how drug company pay-offs cost consumers billions.
Product Details
Nova Science Publishers Inc
73110
9781611220711
9781611220711

Data sheet

Publication date
2011
Issue number
1
Cover
hard cover
Dimensions (mm)
230.00 x 155.00
Weight (g)
316
  • Preface; Pay-for-Delay:: How Drug Company Pay-Offs Cost Consumers Billions; Pay-for-Delay Settlements in the Pharmaceutical Industry:: How Congress Can Stop Anticompetitive Conduct, Protect Consumers Wallets, & Help Pay for Health Care Reform (The $35 Billion Solution); Statement of The Federal Trade Commission, before the Subcommittee on Courts & Competition Policy, Hearing on Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry:: Why Consumers & the Federal Government are Paying Too Much for Prescription Drugs; Testimony of Heather Bresch, Chief Operating Officer, Mylan, Inc, before the Subcommittee on Courts & Competition Policy, Hearing on Pay to Delay:: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive; Testimony of Bret M Dickey, Senior Vice President, Compass Lexecon, before the Subcommittee on Courts & Competition Policy, Hearing on Pay to Delay:: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive; Statement of Guy Donatiello, Endo Pharmaceuticals Inc., before the Subcommittee on Courts & Competition Policy, Hearing on Pay to Delay:: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive; Statement of William P. (Bill) Kennedy, Co-Owner, Nephron Pharmaceuticals Corporation, before the U.S. House of Representatives, Hearing on H.R. 1706, the Protecting Consumer Access to Generic Drugs Act of 2009; Testimony of William Vaughan, Senior Health Analyst, Consumers Union, Non-Profit Publisher of Consumer Reports, before the Subcommittee on Courts & Competition Policy, Hearing on Pay to Delay:: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive; Index.
Comments (0)
Viewed products

  • Frequently purchased together

    No products available